Astellas Pharma Inc. – Product Pipeline Review – 2013

Date: April 30, 2013
Pages: 353
Price:
US$ 1,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A5D6940CB87EN
Leaflet:

Download PDF Leaflet

Astellas Pharma Inc. – Product Pipeline Review – 2013
Astellas Pharma Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Astellas Pharma Inc. - Product Pipeline Review - 2013” provides data on the Astellas Pharma Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Astellas Pharma Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Astellas Pharma Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Astellas Pharma Inc. - Brief Astellas Pharma Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Astellas Pharma Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Astellas Pharma Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Astellas Pharma Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate Astellas Pharma Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Astellas Pharma Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Astellas Pharma Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Astellas Pharma Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Astellas Pharma Inc. and identify potential opportunities in those areas.
Astellas Pharma Inc. Snapshot
Astellas Pharma Inc. Overview
Key Information
Key Facts
Astellas Pharma Inc. – Research and Development Overview
Key Therapeutic Areas
Astellas Pharma Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Astellas Pharma Inc. – Pipeline Products Glance
Astellas Pharma Inc. – Late Stage Pipeline
Astellas Pharma Inc. Clinical Stage Pipeline Products
Astellas Pharma Inc. – Early Stage Pipeline Products
Astellas Pharma Inc. – Drug Profiles
(solifenacin succinate + tamsulosin hydrochloride)
Activated CDC42 Kinase 1 Inhibitors
Advagraf + Mycophenolate Mofetil + Methylprednisolone
AGS-16C3F
AGS-16M8F
AS-1669058
AS-1708727
AS-1842856
AS-1940477
AS-2521780
ASG-22-ME
ASG-5-ME
ASP-0113
ASP-015-K
ASP-0306
ASP-0777
ASP-1707
ASP-1941 + [voglibose]
ASP-2408
ASP-2409
ASP-3026
ASP-3258
ASP-3652
ASP-4901
ASP-6432
ASP-6537
ASP-7035
ASP-7663
ASP-7991
ASP-8232
ASP-8477
ASP-9133
ASP-9226
ASP-9603
ASP-9853
bendamustine hydrochloride
beraprost sodium
Compound 24g
Compound-1
Drug For Alzheimer’s Disease
Drug Program For Neglected Tropical Diseases
erlotinib hydrochloride
FK-886
Human Antibody For Infectious Diseases
ipragliflozin
ipragliflozin + [metformin]
ipragliflozin + [nateglinide]
ipragliflozin + [pioglitazone hydrochloride]
linsitinib
linsitinib + [bortezomib] + [dexamethsone]
linsitinib + [erlotinib]
linsitinib + [paclitaxel]
micafungin sodium
mirabegron
mirabegron + solifenacin succinate
OSI-027
PQIP
quetiapine fumarate ER
ramosetron
sepantronium bromide
sepantronium bromide + [docetaxel]
sepantronium bromide + [rituximab]
solifenacin succinate
sulindac
tacrolimus ER
Tarceva + Gemcitabine + Nab-Paclitaxel
Vascular Adhesion Protein-1 Inhibitor
Astellas Pharma Inc. – Pipeline Analysis
Astellas Pharma Inc. – Pipeline Products by Therapeutic Class
Astellas Pharma Inc. – Pipeline Products by Route of Administration
Astellas Pharma Inc. – Pipeline Products By Mechanism of Action
Astellas Pharma Inc. – Recent Pipeline Updates
Astellas Pharma Inc. - Dormant Projects
Astellas Pharma Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Astellas Pharma Inc. – Company Statement
Astellas Pharma Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Astellas Pharma Inc. - Key Manufacturing Facilities
Astellas Pharma Inc., Recent Developments
Astellas Pharma Inc.- Press Release
Financial Deals Landscape
Astellas Pharma Inc., Deals Summary
Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Venture Financing
Partnerships
Licensing Agreements
Asset Transactions
Acquisition
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Astellas Pharma Inc., Key Information
Astellas Pharma Inc., Key Facts
Astellas Pharma Inc. – Pipeline by Indication, 2013
Astellas Pharma Inc. – Pipeline by Stage of Development, 2013
Astellas Pharma Inc. – Monotherapy Products in Pipeline, 2013
Astellas Pharma Inc. – Combination Treatment Modalities in Pipeline, 2013
Astellas Pharma Inc. – Filed, 2013
Astellas Pharma Inc. – Filing Rejected/Withdrawn, 2013
Astellas Pharma Inc. – Phase III, 2013
Astellas Pharma Inc. – Phase II, 2013
Astellas Pharma Inc. – Phase I, 2013
Astellas Pharma Inc. – Pre-Clinical, 2013
Astellas Pharma Inc. – Discovery, 2013
Astellas Pharma Inc. – Pipeline By Therapeutic Class, 2013
Astellas Pharma Inc. – Pipeline By Route of Administration, 2013
Astellas Pharma Inc. – Pipeline Products By Mechanism of Action, 2013
Astellas Pharma Inc. – Recent Pipeline Updates, 2013
Astellas Pharma Inc. - Dormant Developmental Projects,2013
Astellas Pharma Inc. - Discontinued Pipeline Products, 2013
Astellas Pharma Inc., Other Locations
Astellas Pharma Inc., Subsidiaries
Astellas Pharma Inc., Key Manufacturing Facilities
Astellas Pharma Inc., Deals Summary
MediGene Completes Sale Of European Rights For Eligard To Astellas
Astellas Pharma Acquires Assets And Rights Of Diannexin From Alavita Pharma
Agensys Secures $41 Million In Series D Financing
Astellas Pharma Enters Into Co-Development Agreement With Ambrx
Astellas Pharma Enters Into Research Agreement With Nagasaki University
Astellas Pharma Enters Into Research Agreement With Tokyo Institute of Technology
Humana Enters Into Research Agreement With Astellas For Health Care Delivery
University of Tokyo Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs
Nagasaki University Enters Into Research Agreement With Astellas Pharma To Discover New Drugs For NTDs
Astellas Pharma Enters Into Drug Discovery Agreement With AIST
KEK Enters Into Research Agreement With Astellas Pharma To Discover Drugs For Infectious Diseases
Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial
Tokyo Institute of Technology Enters Into Research Agreement With Astellas Pharma
TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health
Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases
Kaketsuken Enters Into Co-Marketing Agreement With Astellas Pharma For Polio Vaccine
Pfizer Extends Co-Promotion Agreement With Astellas Pharma For Lipitor
National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma
Astellas Pharma Enters Into Distribution Agreement With Sanwa Kagaku Kenkyusho
Astellas Pharma Enters Into Co-Development Agreement With UCB For Cimzia
RIKEN Brain Science Enters Into Research Collaboration With Astellas Pharma
Teijin Pharma Enters Into Distribution Agreement With Astellas Pharma For Febuxostat
Pfizer Amends Its Co-Promotion Agreement With Astellas Pharma
Astellas Pharma Enters Into Distribution Agreement With Abbott Japan For Luvox
Seattle Genetics Exercises Its Option Co-Development Agreement With Agensys
BioFocus Enters Into Co-Development Agreement With Astellas Pharma
Multiple Myeloma Research Foundation Enters Into Co-Development Agreement With Astellas Pharma
Cell Signaling Technology Enters Into Co-Marketing Agreement With Astellas Pharma
Maruho Enters Into Co-Marketing Agreement With Astellas
Astellas Pharma Enters Into Drug Discovery Collaboration With NITE
Astellas Pharma Enters Into An Agreement With Sanofi-Aventis
Dong-A Pharma Enters Into Co-Promotion Agreement With Astellas Pharma Korea
Astellas Pharma Enters Into Co-Marketing Agreement With Bayer Schering Pharma
OM PHARMA Enters Into Co-Marketing Agreement With Astellas Pharma
Ambit Biosciences Enters Into Co-Development Agreement With Astellas Pharma
Seattle Genetics Expands Collaboration Agreement With Agensys
Medivation Enters Into Co-Development Agreement With Astellas Pharma
Maxygen Forms Joint Venture With Astellas Pharma
Pfizer Enter Into Co-Promotion Agreement With Astellas Pharma
Astellas Pharma Enters Into Co-Promotion Agreement With AstraZeneca
Astellas Pharma Enters Into Co-Promotion Agreement With Zogenix
REGiMMUNE Enters Into Co-Development Agreement With Astellas Pharma
Astellas Pharma Enters Into Agreement With Maxygen
Zeria Pharma Enters Into Agreement With Astellas Pharma
Effector Cell Institute Enters Into Co-Development Agreement With Astellas Pharma
Astellas Pharma Enters Into Co-Development Agreement With Kyoto University
Seattle Genetics And Agensys Enter Into An Agreement
Oncolys BioPharma Enters Into Licensing Agreement With Astellas Pharma
Maxygen Enters Into License Agreement With Perseid Therapeutics
Astellas Pharma Extends Collaboration With MorphoSys
MorphoSys Enters Into Licensing Agreement With Astellas Pharma
Cubist Pharma Enters Into Licensing Agreement With Astellas Pharma For Ceftolozane
Janssen Biotech Enters Into Licensing Agreement With Astellas Pharma For ASP015K
Optimer Pharma Enters Into Licensing Agreement With Astellas Pharma For Fidaxomicin
GVK Biosciences Extends Licensing Agreement With Astellas Pharma
Evec Enters Into Licensing Agreement With Astellas Pharma
MSD Enters Into Licensing Agreement With Astellas US For vernakalant
Vical Enters Into Licensing Agreement With Astellas Pharma For TransVax
Astellas Pharma Enters Into Licensing Agreement With Cardeus Pharma
Astellas Pharma Enters Into Licensing Agreement With AVEO Pharma For Tivozanib
Optimer Pharma Enters Into Licensing Agreement With Astellas Pharma Europe For Fidaxomicin
Astellas Pharma Europe Expands Its Licensing Agreement With TOLMAR For Eligard
Astellas Pharma Extends Licensing Agreement With AstraZeneca
BioWa Enters Into Licensing Agreement With Agensys
Astellas Pharma Enters Into Licensing Agreement With ASKA Pharma For AKP-002
Astellas Pharma Enters Into Licensing Agreement With UMN Pharma
Astellas Pharma Extends Licensing Agreement With Regeneron Pharma
Teijin Pharma Enters Into An Agreement With Astellas Pharma
Basilea Pharmaceutica Enters Into Licensing, Co-Development And Co-Promotion Agreement with Astellas Pharma
Hikma Pharma Enters Into Licensing Agreement With Astellas Pharma
Ironwood Pharma Enters Into Licensing Agreement With Astellas Pharma
Teijin Pharma Enters Into Licensing Agreement With Astellas Pharma Taiwan
Millipore Enters Into Licensing Agreement With Astellas
MorphoSys Enters Into Licensing Agreement With Astellas
GlaxoSmithKline Pharma Enters Into Licensing Agreement With Astellas Pharma
Astellas Pharma Enters Into Licensing Agreement With CoMentis For Beta-Secretase Inhibitors
SymBio Pharma Enters Into Licensing Agreement With Astellas Pharma
Astellas Pharma Enters Into Licensing Agreement With Regeneron Pharma
Astellas Enters Into License Agreement With Kirin Brewery Company
Seldar Pharma To Acquire ASP7147 Compound From Astellas Pharma
Telsar Pharma To Acquire ASP3291 Compound Of Astellas Pharma
Astellas Pharma Acquires Remaining 83% Interest In Perseid Therapeutics From Maxygen
Astellas Pharma Acquires OSI Pharma
Astellas Acquires Agensys
Astellas Pharma Sells Hoshienu Pharma To Choseido Pharma

LIST OF FIGURES

Astellas Pharma Inc. – Pipeline by Indication, 2013
Astellas Pharma Inc. – Pipeline by Stage of Development, 2013
Astellas Pharma Inc. – Monotherapy Products in Pipeline, 2013
Astellas Pharma Inc. – Combination Treatment Modalities in Pipeline, 2013
Astellas Pharma Inc. – Pipeline By Therapeutic Class, 2013
Astellas Pharma Inc. – Pipeline By Route of Administration, 2013
Astellas Pharma Inc. - Pipeline Products By Mechanism of Action, 2013

Ask Your Question

Astellas Pharma Inc. – Product Pipeline Review – 2013
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: